GlassScriptPhysician profile
William Wallace Anderson
NPI 1194800334
$5,582.07
in general payments reported to CMS, 2019-2025
18 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $618 · 2021: $837 · 2022: $1,144 · 2023: $465 · 2024: $346 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.58 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,446.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,043.91 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $492.02 | 2020-2025 | Zepbound |
| Abbvie INC. | $293.87 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $242.72 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $170.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.30 | 2019-2021 | |
| Genentech USA, INC. | $125.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.04 | 2023 | |
| Phathom Pharmaceuticals, INC. | $104.02 | 2025 | Voquezna |
| Abbott Laboratories | $103.22 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $94.20 | 2019 | |
| Merck Sharp & Dohme LLC | $62.18 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $35.67 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $18.46 | 2020 | |
| Medline Industries LP | $17.71 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.